Top 50 Pharmaceutical Companies 2014

Who are the top pharmaceutical companies in the world and what are they worth in 2014? The Pharmaceutical and Biotechnology continue to dominate the world’s R&D expenditure, with more companies in the top 10 than any other sector. This year, whilst Novartis has knocked Roche from their top spot, individual R&D spends by pharma and biotechs fail to compete with …

New Positive Dengue Vaccine Results From Sanofi’s Biggest Trial Yet

Sanofi today announced the positive results of a 20,000 strong phase III trial of their pioneering dengue vaccine This final study from Sanofi Pasteur, Sanofi’s vaccine arm, has demonstrated a 60.8 reduction in cases of dengue  fever amongst it’s 20,875 strong population of 9-16 year olds in Latin America. This was accompanied by a 80% reduction in hospitalisations caused by …

Clinical Trials: Cooperation and Big Data Sharing is the Way Forward

Big Pharma companies are hiring Big Data analytics firms to protect privacy of shared data Important initiatives are emerging for big pharma companies to render their trials results accessible to other companies and to researchers. The spread of this tendency would make drug development more efficient and save the industry billions. Indeed, if researchers could always see which mistakes rivals …

privacy analytics pharma

Privacy Analytics releases solution to share anonymised clinical trials data

  A leading provider of data anonymisation solutions for the health care industry has announced the release of a new solution that enables companies to share clinical trials data while protecting the privacy of individual participants. Privacy Analytics’ Open Clinical Trials Data Review identifies privacy gaps in sharing clinical trials data, by relying on the company’s PARAT software, which automates …

Sanofi plans China growth with 4 new plants

Sanofi plans to open four manufacturing plants this year in China, reports the Wall Street Journal. The WSJ reports that Sanofi expects to see "double-digit sales growth" in the next five years in China, and plans to expand its animal health and vaccine business in the country. The French pharmaceutical company currently has six plants in China, but the addition …

“Crowd sourcing drug development”. Can it really lead to drug repositioning?

After the NCATS pilot program ‘Discovering New Therapeutic Uses for Existing Molecules' was launched in May, a lot has been discussed about its potential and the actual feasibility to reposition one or some of the 58 compounds contributed by the eight big pharma joining the project. Experts in the field of drug repurposing say that there's very little opportunity for …

New format European Antibody Congress 2012

More topics. More networking. More opportunities In 2012, the 8th Annual European Antibody Congress has evolved to differentiate itself and provide the most comprehensive and focused forum for the antibody industry. This year, we`re bringing you more specific content, more KOLs, more 1-2-1 interactions and more reasons to bring your team! The Monocloncal Antibody Track will focus on all things …

Key Figures and Top Rankings in the BioPharma Industry

According to EvaluatePharma, there is going to be some reshuffling of the top pharma rankings . It is estimated that in 2018, Novartis will be overtaking Pfizer as the top pharmaceutical company (ranked by prescription-drug revenue), with Sanofi coming in third position. Runner-ups include GlaxoSmithKline, Roche and Merck & Co. respectively. The top 6 pharmas are estimated to enjoy sales …

“#Pharmaceutical companies realise they need to become more #social

Pharmaceutical companies have already realised that traditional forms of marketing no longer cut it if they want to be leaders in the industry. Social media has been an aspect of #digital marketing that the pharmas have been nervous in their approach. Many are deterred by guidelines set by government, but as Pat Choumitsky, senior manager of consumer marketing, UCB Pharma, …

How Genzyme created the critical elements of #orphandrug success #raredisease

Possibly the most significant announcement in the orphan drug and rare disease industry in 2011 was Paris based pharmaceutical giant Sanofi's acquisition of Genzyme, a pioneer in the field of rare disease research. In 2011, the World Orphan Drug Congress was privileged to welcome the newly announced Chief Executive Officer of Genzyme, David Meeker to deliver an opening keynote to …